Research across Cancer
Related studies from across the Cancer family.
Case report on VMAT radiotherapy for inoperable anal Buschke-Lowenstein tumors
Radiotherapy offers hope for rare anal tumors in two patients
This case report with literature review describes two patients with inoperable anal Buschke-Lowenstein tumors treated with definitive radiot…
Two patients with inoperable anal tumors showed clinical improvement after receiving definitive radiotherapy, suggesting a viable option for…
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation
Low blood counts and high inflammation may signal worse survival for anal cancer patients
This systematic review and meta-analysis of 3589 patients with anal squamous cell carcinoma found that elevated neutrophil-to-lymphocyte rat…
For patients with anal cancer, low hemoglobin and high inflammation markers linked to poorer survival in this analysis of nearly 3,600 peopl…
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.